ProtoPharma Ltd., a subsidiary of LondonPharma Ltd., is a British company located in King's Lynn. The firm engages in research and development of drugs. It was founded by Calvin John Ross.

KPC is a pharmaceutical company that engages in the manufacture of pharmaceuticals. Tablets, fluids, ointments, and injectables are among their offerings. Its goal is to improve people's lives by enabling them to achieve more, feel better, and live longer. They have technological machinery, skilled and motivated individuals, and management systems that can handle both quantity and quality of work. They are looking for new ways to improve their performance, raise their integrity to a level of excellence, implement their initiatives, and achieve their goals.

Malaria Research Co. Pty Ltd. develops pharmaceuticals segment for the treatment of malaria. Its product includes ArtiMist, sublingual anti-malarial spray for the treatment of Plasmodium falciparum pediatric malaria. The company is headquartered in Osborne Park, Australia.

Dafra Pharma is a Belgian pharmaceutical group of companies that aims at improving the public health in sub-Saharan Africa.

Engages in biopharmaceutical research and development

Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland.

Desino was founded in 1996 and is headquartered in Shanghai Zhangjiang Hi-Tech Park. The company's anti-AIDS drugs and anti-malarial drugs are the core development areas for the global public health crisis, and are committed to the development, production, registration and global sales of high-quality drugs.The Dyson Company R&D Center is located in Shanghai and is the National Enterprise Technology Center, the National Anti-AIDS Drug Engineering Technology Research Center and the National Postdoctoral Research Station.

Shanghai Desano Chemical Pharmaceutical Co., Ltd., established on 2002-05-16, Business scope includes chemical products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals)Sales,Engaged in the import and export of goods and technology;API production(Stavudine,zidovudine,Lamivudine,Nevirapine,artemether,benzefantrine,Efavirenz,Ritonavir,Emtricitabine,Tenofovir disoproxil fumarate,Valacyclovir Hydrochloride,artesunate);Environmental Protection Engineering,Technology development in the specialized field of industrial and domestic wastewater treatment,technical consulting,Technical Services,technology transfer,Noise and Air Pollution Control. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Henan Heima Animal Pharmaceutical Co., Ltd., established on 2008-06-11, The business scope includes the production of veterinary drugs,Sales,Feed premix and feed additive production,Sales;import and export trade;Pet Supplies Sales;Sales of pet food products;Pet grooming service.

Wasion Biopharmaceutical (Suzhou) Co., Ltd., established on 2012-11-01, The business scope includes the production of artemisinin derivatives,Vinpocetine API,Compound Artemether Tablets and Vinpocetine Tablets,Sell ​​self-produced products(Can only be operated after receiving a license);Biotechnology R&D,Technical service and technology transfer,and related technology imports,Chemical raw materials and products(Excluding hazardous chemicals),Biological product(Hazardous Chemicals,Except for drugs that need to be approved)Wholesale and import and export business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:pharmaceutical production;Pharmaceutical commissioned production;Drug import and export;Import and export;Technology Import and Export;Import and export agency;Production of Class II Medical Devices;Production of medical masks;Production of protective equipment for medical personnel(Class II medical device)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Chemical product production(No licensed chemical products);Chemical product sales(No licensed chemical products);Manufacturing of daily chemical products;Sales of daily chemical products;Cosmetics Wholesale;Cosmetics Retail;Biochemical product technology research and development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Food Additive Sales;Sales of Class II Medical Devices;Wholesale medical masks;Medical Mask Retail;daily mask(non-medical)Production;daily mask(non-medical)Sales;Production of labor protection products;Sales of labor protection products;Wholesale of protective equipment for medical staff;Retailing of protective equipment for healthcare workers(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

SeQuent Scientific Limited is an India-based integrated pharmaceutical company. The Company engaged in developing products and services for a variety of industries, such as pharmaceuticals, agrochemicals, plastics, personal care (cosmetics). The Company operates in three segments include active pharmaceutical ingredients (API), Analytical Services and Animal Health. The Company’s products range from APIs and pharmaceutical intermediates to phyto chemicals and specialty chemicals for industrial use and research. The Company's APIs in human health sector include Albendazole, Lumefantrine, Midazolam, Artesunate, Imiquimod and Miconazole Nitrate, among others. The Company’s APIs in animal health include Albendazole, Buparavaquone, Butaphosphan and Nitroscanate, among others.

Kunyao Group Chongqing Wulingshan Pharmaceutical Co., Ltd., established on 1986-12-24, Business scope includes general items:syrup,API(tannins,artemisinin,Dihydroartemisinin,artesunate,artemether),tablet production,Pharmaceutical Intermediates,Production and sales of plant extracts(Engage in business according to the time limit and scope approved by the administrative license);Chinese herbal medicine planting,First Processing,Sales,scientific research and development,technical consulting,Serve;New product transfer of Chinese herbal medicines;Wujinjiaodian,Chemical Products,building materials,department store,Grocery retail;Acquisition of Chinese herbal medicines,Manage the export business of the company's self-produced products and the machinery and equipment needed by the company,Import business of raw and auxiliary materials for spare parts,However, the state restricts the company to operate or prohibits the import and export of goods except.(Export Commodity Catalog Artemisinin produced by the company,Commodities such as artemether capsules and related technologies.The imported commodity catalog is the raw and auxiliary materials required by the enterprise,Equipment,Instrumentation,Parts and related technologies)[Those prohibited by laws and regulations in the scope of business shall not operate,Laws and regulations require approval to obtain a license,Can only be operated after obtaining the approval of the license](Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shanghai Baina Pharmaceutical Technology Co., Ltd., established on 2012-02-29, The scope of business includes engaging in medical technology,Technology development in the field of biotechnology,technical consulting,technology transfer,Technical Services,Chemical products and raw materials(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals),cosmetic,Packaging Materials,laboratory consumables,Instrumentation,Sales of Electronics,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Guangzhou General Pharmaceutical Research Institute Co. Ltd., a subsidiary of City of Guangzhou, is a Chinese company located in Guangzhou that provides pharmaceutical research and development services. On December 17, 2014 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. acquired Guangzhou General Pharmaceutical Research Institute Co. Ltd. from Guangzhou Pharmaceutical Holdings Ltd. for $25.88 million.

Henan Huamu Biotechnology Co., Ltd., established on 2007-08-08, Business scope includes licensed projects:Veterinary drug production;Veterinary drug business;pharmaceutical production;Drug import and export;Import and export;feed production;Feed additive production;Disinfectant production(Free of Hazardous Chemicals);Health food production;Health food sales;Cosmetic production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Feed Raw Material Sales;Feed Additive Sales;Disinfectant sales(Free of Hazardous Chemicals);Daily necessities sales;internet sales(Except for products that require a license for sale);Chinese herbal medicine planting;Cosmetics Wholesale;Bio-feed R&D;Research and development of technology for the harmless utilization of agricultural and forestry waste resources;production of agricultural products,Sales,processing,transportation,Storage and other related services;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany.

Xi’an Libang Enterprises, established in 1996, a hi-tech biopharmaceutical-oriented corporate group specialized in the development, production and distribution of pharmaceutical products and healthy nutrition products, also presenting in the cultural industry.